Trial: 202104068

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects with De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

Phase

I

Principal Investigator

Reimers, Melissa

Disease Site

Prostate

Learn more about this study at: clinicaltrials.gov